SOD1 A4V

Superoxide dismutase 1 (SOD1) is an enzyme that protects cells from oxidative damage by converting harmful superoxide radicals into less reactive molecules. Mutations in the SOD1 gene account for approximately 2% of all ALS cases and roughly 20% of familial (inherited) ALS [5]. The A4V mutation, where alanine at position 4 is replaced by valine, is particularly significant as it represents one of the most common and aggressive SOD1 mutations found in North American ALS patients. Unlike some SOD1 variants that show incomplete penetrance (meaning not everyone with the mutation develops disease), A4V typically causes rapid disease progression [3]. The AlphaFold2 structure prediction for SOD1 A4V achieved an exceptionally high average confidence score of 97.7% pLDDT (predicted Local Distance Difference Test), indicating that the computational model is highly reliable across nearly all regions of the protein. This high confidence level allows for detailed analysis of how the mutation might affect protein structure and stability. The mutation occurs at position 4, very near the N-terminus (beginning) of the protein, which could influence how the protein folds initially and maintains its structural integrity over time. SOD1 mutations are thought to cause ALS not by eliminating the protein's normal antioxidant function, but rather by causing the mutant protein to misfold and form toxic aggregates that accumulate in motor neurons. Research has demonstrated that various SOD1 mutations, including those affecting different residues, can destabilize the protein's local structure and promote aggregation into beta-sheet-rich amyloid fibrils that are toxic to cells [2]. The position of the A4V mutation near the N-terminus may particularly affect protein stability during the early stages of folding, potentially explaining its aggressive clinical phenotype. Studies of other SOD1 mutations have shown that even single amino acid changes can dramatically alter disease progression rates and clinical presentations [1][6]. The structural insights from this analysis are clinically relevant given recent therapeutic advances. Tofersen, an antisense oligonucleotide drug that reduces production of mutant SOD1 protein by degrading its messenger RNA, has been approved for treating SOD1-related ALS [5]. Understanding the precise structural consequences of different SOD1 mutations like A4V can help predict which patients might benefit most from such targeted therapies and inform the development of additional structure-based therapeutic approaches. The high-confidence structural model generated here provides a valuable resource for designing experiments to test how the A4V mutation affects protein stability, aggregation propensity, and interactions with other cellular components. Clinically, SOD1-related ALS shows considerable phenotypic variability, with some mutations predominantly affecting lower motor neurons while others show more mixed or even upper motor neuron predominance [4]. Understanding the structural basis for these differences remains an important research goal. The comprehensive genetic testing now available has revealed that disease-causing variants occur in 10-15% of apparently sporadic ALS cases, underscoring the importance of genetic screening and mutation-specific structural analysis for all ALS patients [7][8].